AVIR

Atea Pharmaceuticals Stock Price

23.58
-0.23 (-0.97%)
Upgrade to Real-Time
Afterhours (Closed)
23.58

Low
18.72

52 Week Range

High
94.1737

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Atea Pharmaceuticals Inc AVIR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.23 -0.97% 23.58 19:03:25
Open Price Low Price High Price Close Price Prev Close
23.66 22.74 23.84 23.58 23.81
Bid Price Ask Price Spread News
23.80 25.00 1.20 - 1
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
9,757 1,556,741 $ 23.38 $ 36,403,515 996,844 18.72 - 94.1737
Last Trade Time Type Quantity Stock Price Currency
19:38:25 9 $ 23.58 USD

Atea Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.95B 82.74M 61.02M $ 48.63M $ 10.08M -0.63 -113.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 56.67k 1.90%

more financials information »

Atea Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AVIR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week24.1325.5722.6924.071,156,865-0.55-2.28%
1 Month23.5025.5719.4722.40971,7820.080.34%
3 Months77.4177.9118.7229.34899,191-53.83-69.54%
6 Months31.4294.173718.7238.09586,275-7.84-24.95%
1 Year29.9494.173718.7236.92569,949-6.36-21.24%
3 Years29.9494.173718.7236.92569,949-6.36-21.24%
5 Years1.3694.17370.43116.32356,42922.221,633.82%

Atea Pharmaceuticals Description

Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.


Your Recent History
NASDAQ
AVIR
Atea Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.